Cargando…

Vaccine Therapy in Non-Small Cell Lung Cancer

Immunotherapy using immune checkpoint modulators has revolutionized the oncology field, emerging as a new standard of care for multiple indications, including non-small cell lung cancer (NSCLC). However, prognosis for patients with lung cancer is still poor. Although immunotherapy is highly effectiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	García-Pardo, Miguel, Gorria, Teresa, Malenica, Ines, Corgnac, Stéphanie, Teixidó, Cristina, Mezquita, Laura
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146850/ https://www.ncbi.nlm.nih.gov/pubmed/35632496 http://dx.doi.org/10.3390/vaccines10050740

Ejemplares similares

Integrin-α(V)-mediated activation of TGF-β regulates anti-tumour CD8 T cell immunity and response to PD-1 blockade
por: Malenica, Ines, et al.
Publicado: (2021)

Prospective Evaluation of Single Nucleotide Variants by Two Different Technologies in Paraffin Samples of Advanced Non-Small Cell Lung Cancer Patients
por: Marin, Elba, et al.
Publicado: (2020)

The role of brigatinib in crizotinib-resistant non-small cell lung cancer
por: Mezquita, Laura, et al.
Publicado: (2018)

Mutant and non-mutant neoantigen-based cancer vaccines: recent advances and future promises
por: Ashi, Mohamad Omar, et al.
Publicado: (2022)

Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing
por: Leclerc, Marine, et al.
Publicado: (2019)

PD-L1 expression testing in non-small cell lung cancer
por: Teixidó, Cristina, et al.
Publicado: (2018)

Resident memory T cells, critical components in tumor immunology
por: Mami-Chouaib, Fathia, et al.
Publicado: (2018)

Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy
por: Albarrán-Artahona, Víctor, et al.
Publicado: (2022)

CD103(+)CD8(+) T(RM) Cells Accumulate in Tumors of Anti-PD-1-Responder Lung Cancer Patients and Are Tumor-Reactive Lymphocytes Enriched with Tc17
por: Corgnac, Stéphanie, et al.
Publicado: (2020)

The Lung Immune Prognostic Index (LIPI) stratifies prognostic groups in advanced non-small cell lung cancer (NSCLC) patients
por: Aldea, Mihaela, et al.
Publicado: (2020)

P09.15 Severity of Lung Cancer Disease in Hospitalized Patients During COVID-19
por: Fernández-Mañas, L., et al.
Publicado: (2021)

AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy
por: Bertran-Alamillo, Jordi, et al.
Publicado: (2019)

Comment on Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176
por: Auclin, Edouard, et al.
Publicado: (2021)

Liquid Biopsy in Non-Small Cell Lung Cancer
por: Molina-Vila, Miguel A., et al.
Publicado: (2016)

Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience
por: Botticella, Angela, et al.
Publicado: (2019)

Isolation of tumor-resident CD8(+) T cells from human lung tumors
por: Corgnac, Stéphanie, et al.
Publicado: (2021)

P09.28 Access to Intermediate and Intensive Care for Patients With Lung Cancer During the COVID-19 Period
por: Gorría, T., et al.
Publicado: (2021)

Response to crizotinib in a non-small-cell lung cancer patient harboring an EML4-ALK fusion with an atypical LTBP1 insertion
por: Aguado, Cristina, et al.
Publicado: (2018)

PD-L1 Expression in Non-Small Cell Lung Cancer: Data from a Referral Center in Spain
por: Saez de Gordoa, Karmele, et al.
Publicado: (2021)

Management of Resectable Stage III-N2 Non-Small-Cell Lung Cancer (NSCLC) in the Age of Immunotherapy
por: Mielgo-Rubio, Xabier, et al.
Publicado: (2021)

Updated Views in Targeted Therapy in the Patient with Non-Small Cell Lung Cancer
por: Ortega, Miguel A., et al.
Publicado: (2023)

Therapeutic vaccines in non-small cell lung cancer
por: Socola, Francisco, et al.
Publicado: (2013)

EBUS-TBNA Cytological Samples for Comprehensive Molecular Testing in Non–Small Cell Lung Cancer
por: Martin-Deleon, Roberto, et al.
Publicado: (2021)

iNKT/CD1d-antitumor immunotherapy significantly increases the efficacy of therapeutic CpG/peptide-based cancer vaccine
por: Corgnac, Stéphanie, et al.
Publicado: (2014)

Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients
por: Karachaliou, Niki, et al.
Publicado: (2018)

Deep diving in the PACIFIC: Practical issues in stage III non-small cell lung cancer to avoid shipwreck
por: Mielgo-Rubio, Xabier, et al.
Publicado: (2020)

Targeted therapies in non-small cell lung cancer
por: Kyle, Fiona, et al.
Publicado: (2008)

Maintenance Therapies for Non-Small Cell Lung Cancer
por: Blais, Normand, et al.
Publicado: (2014)

The Evolution of Therapies in Non-Small Cell Lung Cancer
por: Boolell, Vishal, et al.
Publicado: (2015)

Emerging therapies for non-small cell lung cancer
por: Zhang, Chao, et al.
Publicado: (2019)

Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond
por: Delaney, Christopher, et al.
Publicado: (2015)

Tumor-resident memory T cells as a biomarker of the response to cancer immunotherapy
por: Damei, Isabelle, et al.
Publicado: (2023)

Multiplex RNA‐based detection of clinically relevant MET alterations in advanced non‐small cell lung cancer
por: Aguado, Cristina, et al.
Publicado: (2020)

HER2 in Non-Small Cell Lung Cancer: A Review of Emerging Therapies
por: Uy, Natalie F., et al.
Publicado: (2022)

Radon and Lung Cancer: Current Trends and Future Perspectives
por: Riudavets, Mariona, et al.
Publicado: (2022)

Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy
por: Durgeau, Aurélie, et al.
Publicado: (2018)

Actual status of therapeutic vaccination in non-small cell lung cancer
por: Szyszka-Barth, Katarzyna, et al.
Publicado: (2014)

Prospective analysis of liquid biopsies of advanced non-small cell lung cancer patients after progression to targeted therapies using GeneReader NGS platform
por: Mayo de las Casas, Clara, et al.
Publicado: (2019)

Targeted therapies in development for non-small cell lung cancer
por: Reungwetwattana, Thanyanan, et al.
Publicado: (2013)

Targeted therapies for advanced non-small cell lung cancer
por: Ai, Xiaojuan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_pjq7dv2lv7i3jl63kn7dn6lr1t